SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stressgen (VSE: SSB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Heat Shock who wrote (100)10/23/1999 12:21:00 PM
From: Heat Shock  Read Replies (1) of 236
 
To all: Looks like a perfect choice to head up the Phase 2 HspE7 trial against anal dysplasia. J Palefsky describes his research at UCSF:

My laboratory focuses on the mechanisms by which DNA tumor viruses, i.e. human papillomavirus (HPV) and Epstein-Barr Virus (EBV) interact with epithelial cells to promote the development of epithelial neoplasia. At the clinical level, our work on HPV focuses on HPV infection in immunocompromised host and its role in the pathogenesis of anal, cervical and oral cancer. At a basic level, we are currently characterizing mechanisms of T cell immunity to HPV, and are developing an in-vitro model of tumor cell invasion by HPV-transformed epithelial cells. This work includes identification of proteases, autocrine and paracrine factors involved in cell invasion and the molecular mechanisms by which HPV cellular genes contribute to this process.

Here is his bio:

cc.ucsf.edu

Heat
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News